Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen
Sponsors
Novo Nordisk A/S
Conditions
Participants with T2D and overweightType 1 DiabetesType 2 DiabetesType 2 diabetesType 2 diabetes (T2D) and increased cardiovascular (CV) risk not in adequate glycaemic control on 1–3 marketed oral glucose lowering medications.
Phase 3
A Study to Evaluate the Efficacy and Safety of Once-weekly Insulin Icodec when Switching from Daily Basal Insulins Compared to Once-daily Insulin Glargine U100 in Adults with Type 2 Diabetes
CompletedCTIS2023-506084-34-00
Start: 2024-04-12End: 2025-06-13Target: 145Updated: 2025-04-17
Efficacy and safety of once-weekly semaglutide s.c. 2.0 mg as add-on to dose-reduced insulin glargine vs titrated insuline glargine in participants with type 2 diabetes and overweight
CompletedCTIS2024-510612-75-00
Start: 2022-08-31End: 2025-04-01Target: 398Updated: 2025-03-12
A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination with Insulin Aspart, in Adults with Type 1 Diabetes
RecruitingCTIS2024-519945-31-00
Start: 2025-08-21Target: 242Updated: 2025-10-15
Efficacy and safety of zenagamtide s.c. once weekly compared to insulin glargine s.c. once daily in participants with type 2 diabetes and increased cardiovascular risk inadequately controlled on 1–3 oral glucose-lowering medications (AMBITION 7)
WithdrawnCTIS2026-525209-11-00
Target: 110Updated: 2026-09-04